HWHG: Oxcarbazepine extended-release tablets received a tentative approval number from the U.S. FDA
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, HWHG announced that its holding subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd. (referred to as "Renfulikang"), has received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine Extended-Release Tablets. Oxcarbazepine Extended-Release Tablets are used to treat partial seizures in patients aged 6 years and older with epilepsy
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments